Dec 3, 2025 11:44AM Pharvaris B.V. (PHVS) PT Raised to $30 at BofA Securities

Dec 3, 2025 06:50AM Pharvaris reports positive results from HAE treatment study

Nov 21, 2025 07:05AM Pharvaris B.V. (PHVS) Stock Setup is Strong - Cantor Fitzgerald

Nov 19, 2025 04:26AM Pharvaris B.V.'s (PHVS) Improving Profile Can Send Shares Up >$30s - Citizens

Oct 23, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Pharvaris B.V. (PHVS)

Oct 15, 2025 06:06AM H.C. Wainwright Starts Pharvaris B.V. (PHVS) at Buy

Oct 8, 2025 04:16PM BofA Securities Upgrades Pharvaris B.V. (PHVS) to Neutral 'on potential label expansion for angioedema treatment'

Aug 13, 2025 04:07AM Pharvaris B.V. (PHVS) PT Lowered to $52 at Citizens JMP

Jul 10, 2025 11:17AM BofA Securities Reiterates Underperform Rating on Pharvaris B.V. (PHVS)

Jul 10, 2025 06:51AM Pharvaris delays RAPIDe-3 study results to Q4 2025

Jun 27, 2025 06:50AM Pharvaris (PHVS) to Present Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE

Jun 16, 2025 06:50AM Pharvaris (PHVS) Presents Data Highlighting the Potential for Deucrictibant

Jun 5, 2025 04:20AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Jun 2, 2025 06:52AM Pharvaris (PHVS) Presents Data Supporting Ongoing Clinical Development of Deucrictibant

Apr 23, 2025 04:23AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Apr 1, 2025 06:50AM Pharvaris (PHVS) Granted Orphan Designation to Deucrictibant in the EU

Mar 3, 2025 06:50AM Pharvaris (PHVS) Presents Long-Term Clinical Data of Deucrictibant

Mar 3, 2025 04:49AM Citizens JMP Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Feb 18, 2025 04:15AM JMP Securities Reiterates Market Outperform Rating on Pharvaris B.V. (PHVS)

Jan 31, 2025 04:40AM Pharvaris B.V. (PHVS) PT Raised to $55 at JMP Securities

Jan 13, 2025 06:52AM Pharvaris (PHVS) Outlines 2025 Strategic Priorities

Oct 16, 2024 06:51AM Pharvaris (PHVS) to Present Data Highlighting Deucrictibant for the Treatment of HAE

Oct 14, 2024 06:08AM Oppenheimer Reiterates Outperform Rating on Pharvaris B.V. (PHVS)

Oct 3, 2024 06:50AM Pharvaris (PHVS) Announces Data Highlighting Deucrictibant for the Treatment of HAE

Sep 19, 2024 09:33AM Jones Trading Starts Pharvaris B.V. (PHVS) at Buy

Sep 6, 2024 05:07AM Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer

Sep 5, 2024 06:50AM Pharvaris (PHVS) Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE

Sep 5, 2024 06:50AM Pharvaris (PHVS) Provides Business Update, Expands Development Program for Deucrictibant

Jul 3, 2024 05:54AM Pharvaris B.V. (PHVS) PT Raised to $38 at Oppenheimer